ESR2 and breast cancer: Thus, in summary, analysis of the HPCCC fractions revealed divergence of the previously demonstrated positive estrogenic attributes of the NPF into separate fractions, with F1 and F2 retaining ERα antagonism, only F2 retaining antagonism of E2 induced breast cancer cell proliferation, and only F3 retaining ERβ agonist activity.